Log in
Enquire now
‌

US Patent 7368463 Substituted 4-amino-1-benzylpiperidine compounds

Patent 7368463 was granted and assigned to Theravance on May, 2008 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Theravance
Theravance
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
73684630
Patent Inventor Names
David Oare0
Sarah Dunham0
Trevor Mischki0
Yu-Hua Ji0
Adam Hughes0
Craig Husfeld0
Ioanna Stergiades0
Li Li0
...
Date of Patent
May 6, 2008
0
Patent Application Number
108888550
Date Filed
July 9, 2004
0
Patent Primary Examiner
‌
Celia Chang
0
Patent abstract

This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7368463 Substituted 4-amino-1-benzylpiperidine compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.